Enhancing the Response Rate to Recombinant Uricases in Patients with Gout
- PMID: 35316517
- PMCID: PMC8938732
- DOI: 10.1007/s40259-022-00517-x
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout
Abstract
Refractory, or uncontrolled, gout is a chronic, progressive, inflammatory arthropathy resulting from continued urate deposition after failed attempts to lower serum uric acid below the therapeutic threshold with oral urate-lowering therapies such as allopurinol and febuxostat. Recombinant uricase is increasingly being used to treat refractory gout; however, the immunogenicity of uricase-based therapies has limited the use of these biologic therapies. Antidrug antibodies against biologic therapies, including uricase and PEGylated uricase, can lead to loss of urate-lowering response, increased risk of infusion reactions, and subsequent treatment failure. However, co-therapy with an immunomodulator can attenuate antidrug antibody development, potentially increasing the likelihood of sustained urate lowering, therapy course completion, and successful treatment outcomes. This review summarizes evidence surrounding the use of immunomodulation as co-therapy with recombinant uricases.
© 2022. The Author(s).
Conflict of interest statement
NS has received grants from Amgen and is a consultant to and advisory board member for Horizon Therapeutics, Alnylam Pharmaceuticals, and JW Pharmaceutical Corporation. BL and LP-S are employees of and stockholders in Horizon Therapeutics.
Figures

Similar articles
-
Mechanisms and rationale for uricase use in patients with gout.Nat Rev Rheumatol. 2023 Oct;19(10):640-649. doi: 10.1038/s41584-023-01006-3. Epub 2023 Sep 8. Nat Rev Rheumatol. 2023. PMID: 37684360 Review.
-
[Gout: an overview of available urate lowering therapies].Ann Pharm Fr. 2012 May;70(3):133-8. doi: 10.1016/j.pharma.2012.02.003. Epub 2012 Apr 27. Ann Pharm Fr. 2012. PMID: 22655581 Review. French.
-
Uricase and other novel agents for the management of patients with treatment-failure gout.Curr Rheumatol Rep. 2007 Jun;9(3):258-64. doi: 10.1007/s11926-007-0041-y. Curr Rheumatol Rep. 2007. PMID: 17531181 Review.
-
Pegloticase for treating refractory chronic gout.Drugs Today (Barc). 2012 Jul;48(7):441-9. doi: 10.1358/dot.2012.48.7.1813475. Drugs Today (Barc). 2012. PMID: 22844655 Review.
-
Update on emerging urate-lowering therapies.Curr Opin Rheumatol. 2009 Mar;21(2):143-9. doi: 10.1097/BOR.0b013e328325bd94. Curr Opin Rheumatol. 2009. PMID: 19339925 Review.
Cited by
-
Biomimetic Integrated Nanozyme for Flare and Recurrence of Gouty Arthritis.Asian J Pharm Sci. 2024 Jun;19(3):100913. doi: 10.1016/j.ajps.2024.100913. Epub 2024 Apr 18. Asian J Pharm Sci. 2024. PMID: 38903129 Free PMC article.
-
Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis.Rheumatol Ther. 2025 Feb;12(1):37-51. doi: 10.1007/s40744-024-00723-9. Epub 2024 Nov 14. Rheumatol Ther. 2025. PMID: 39541087 Free PMC article.
-
Advances in Immune Tolerance Induction in Enzyme Replacement Therapy.Paediatr Drugs. 2024 May;26(3):287-308. doi: 10.1007/s40272-024-00627-9. Epub 2024 Apr 25. Paediatr Drugs. 2024. PMID: 38664313 Free PMC article. Review.
-
Characteristic alterations of gut microbiota in uncontrolled gout.J Microbiol. 2022 Dec;60(12):1178-1190. doi: 10.1007/s12275-022-2416-1. Epub 2022 Nov 24. J Microbiol. 2022. PMID: 36422845
-
Innovative Formulation Platform: Paving the Way for Superior Protein Therapeutics with Enhanced Efficacy and Broadened Applications.Adv Mater. 2024 Oct;36(41):e2403116. doi: 10.1002/adma.202403116. Epub 2024 Jun 16. Adv Mater. 2024. PMID: 38819929 Free PMC article. Review.
References
-
- Varela-Echavarría A, de Oca-Luna RM, Barrera-Saldaña HA. Uricase protein sequences: conserved during vertebrate evolution but absent in humans. FASEB J. 1988;2(15):3092–3096. - PubMed
-
- Terkeltaub R. Gout: diagnosis and management of gouty arthritis and hyperuricemia, 3rd edn. Professional Communications, Inc; 2013.
-
- Edwards NL. Gout. In: Klippel JH, Stone JH, Crofford LJ, White PH, editors. Primer on the rheumatic diseases. New York: Springer New York; 2008. p. 241–62.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical